U.S. markets closed

PharmaCyte Biotech, Inc. (PMCB)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0152-0.0006 (-4.11%)
At close: 3:51PM EDT

PharmaCyte Biotech, Inc.

23046 Avenida de la Carlota
Suite 600
Laguna Hills, CA 92653
United States
917 595 2850
http://www.pharmacyte.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Mr. Kenneth L. WaggonerChairman, CEO, Pres, Gen. Counsel & Sec.316.67kN/A1948
Mr. Carlos A. Trujillo CPA, CPACFO & Director250kN/A1958
Dr. Gerald W. CrabtreeChief Scientific Officer & Director109.67kN/A1941
Dr. Jose L. IglesiasConsulting Chief Medical OfficerN/AN/AN/A
Dr. Hans-Peter HammesMember of Medical & Scientific Advisory Board and ConsultantN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the activation of cancer-killing drugs to the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. PharmaCyte Biotech, Inc. has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and a research agreement with the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.

Corporate Governance

PharmaCyte Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.